Virologic Suppression, Treatment Adherence, and Improved Quality of Life on a Once-Daily Efavirenz-Based Regimen in Treatment-Naïve HIV-1–Infected Patients Over 96 Weeks
- 1 December 2009
- journal article
- research article
- Published by Informa UK Limited in HIV Research & Clinical Practice
- Vol. 10 (6), 375-384
- https://doi.org/10.1310/hct1006-375
Abstract
This study evaluated the long-term efficacy, safety, adherence, and quality of life (QoL) of a once-daily efavirenz-based antiretroviral regimen in two 96-week prospective open-label single-arm studies of treatment-naïve HIV-1-infected patients. Patients received once-daily efavirenz 600 mg and lamivudine 300 mg with either enteric-coated didanosine 400 mg (Daily Antiretroviral Therapy trial [DART] I) or extended-release stavudine 100 mg (DART II). The primary efficacy outcome measure was HIV RNA <400 copies/mL at Week 48. In an intent-to-treat (ITT) analysis, HIV RNA level <400 (<50) copies/mL was reached by 82%(80%) and 74% (72%) of patients at Week 48 in DART I and II. At Week 96, the corresponding values were 74% (68%) and 55% (54%), respectively. Both regimens were well tolerated. There were no discontinuations for virologic failure. Medication adherence assessed by pill counts was above 80% in 90% of the patients in DART I and more than 80% of patients in DART II. Treatment produced a significant improvement in overall QoL. Once-daily efavirenz-based antiretroviral therapy was effective, durable, and well tolerated. In this study, a high level of adherence was achieved with improvement in overall QoL.Keywords
This publication has 16 references indexed in Scilit:
- Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral SuppressionHIV Research & Clinical Practice, 2008
- Class-Sparing Regimens for Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2008
- Adherence in antiretroviral therapy: a review of qualitative studiesAIDS, 2007
- Adherence to antiretroviral therapy: An update of current conceptsCurrent HIV/AIDS Reports, 2004
- Efavirenz for HIV-1 infection in adults: an overviewExpert Review of Anti-infective Therapy, 2004
- Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized studyHIV Medicine, 2004
- Perspectives on Adherence and Simplicity for HIV-Infected Patients on Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- A randomized study comparing instruments for measuring health-related quality of life in _HIV-infected patientsAIDS, 1999
- Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV)Quality of Life Research, 1997